Description
Linastar M 2.5/500 mg combines Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, with Metformin Hydrochloride, a Biguanide, in a single tablet for the management of Type 2 Diabetes Mellitus. This combination therapy is designed to improve glycemic control by addressing multiple pathways of glucose regulation.
-
Linagliptin helps to enhance insulin secretion and reduce glucagon release in a glucose-dependent manner.
-
Metformin works by reducing hepatic glucose production and increasing insulin sensitivity in peripheral tissues.
This combination therapy is used for patients whose diabetes is not well-controlled with diet and exercise alone or in combination with other oral antidiabetic agents.
.webp)
 200MG.webp)
.jpeg)
Change Language